Cited by 360Cancer-related Molecular PathwaysCell death mechanisms and regulationGenomics and Chromatin Dynamics

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site

Takimoto, R, El-Deiry, W S·2000·Oncogene

DOI 10.1038/sj.onc.1203489

Open this paper in CoChat — free account

Abstract

KILLER/DR5, a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor gene, has been shown to be induced by DNA damaging agents and radiation in a p53-dependent manner. Although TRAIL is a potential therapeutic agent for cancer, the induction mechanism of its receptors is poorly understood. Here we show the identification of three p53 DNA-binding sites in the KILLER/DR5 genomic locus located upstream (BS1; -0.82 Kb) of the ATG site, within Intron 1 (BS2; +0.25 Kb downstream of the ATG) and within Intron 2 (BS3; +1.25 Kb downstream of the ATG). A modified p53-binding and immunoselection protocol using a wild-type p53-expressing adenovirus vector (Ad-p53) was used to identify the binding sites and to show that each binding site can bind specifically to wild-type p53 protein (wt-p53). A reporter assay revealed that only BS2 could enhance luciferase expression driven by a basal promoter. We constructed a reporter plasmid carrying the genomic regulatory region of KILLER/DR5 including the three p53 DNA-binding sites but no additional basal promoter. The genomic fragment showed basal transcriptional activity which was induced by wt-p53 but not by mutant p53, and human papilloma virus E6 inhibited the p53-dependent activation. Mutation of BS2 abrogated not only the binding activity of wt-p53 but also the induction of the KILLER/DR5 genomic promoter-reporter gene, indicating that BS2 is responsible for the p53-dependent transactivation of KILLER/ DR5. In p53-wild-type but not -mutant or -null cell lines, doxorubicin treatment stabilized p53 protein, and increased specific binding to BS2 as revealed by EMSA, and upregulated the KILLER/DR5 promoter-luciferase reporter gene. These results suggest that the transactivation of KILLER/DR5 is directly regulated by exogenous or endogenous wt-p53 and establishes KILLER/DR5 as a p53 target gene that can signal apoptotic death.

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1203489

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Mitochondria and Apoptosis
Green, D. R., & Reed, J. C. (1998) · Science · doi:10.1126/science.281.5381.1309 · Cited by 9,051
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Self-citation
Death Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866
Apoptosis by Death Factor
Nagata, S. (1997) · Cell · doi:10.1016/s0092-8674(00)81874-7 · Cited by 4,934
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Self-citation
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,911
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
A model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Self-citation

Show all 39 references

Sorted by citations

Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
Fulda, S., & Debatin, K.-M. (2006) · Oncogene · doi:10.1038/sj.onc.1209608 · Cited by 2,312
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921
Census and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971
CHOP Is Involved in Endoplasmic Reticulum Stress-induced Apoptosis by Enhancing DR5 Expression in Human Carcinoma Cells
Yamaguchi, H., & Wang, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406933200 · Cited by 825
From bench to clinic with apoptosis-based therapeutic agents
Nicholson, D. W. (2000) · Nature · doi:10.1038/35037747 · Cited by 685
Death receptors in chemotherapy and cancer
Debatin, K., & Krammer, P. H. (2004) · Oncogene · doi:10.1038/sj.onc.1207558 · Cited by 505
BCL2 family in DNA damage and cell cycle control
Zinkel, S. S., Gross, A., & Yang, E. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401987 · Cited by 479
REDD1, a Developmentally Regulated Transcriptional Target of p63 and p53, Links p63 to Regulation of Reactive Oxygen Species
Ellisen, L. W., Ramsayer, K. D., Johannessen, C. M., Yang, A., Beppu, H., Minda, K., Oliner, J. D., McKeon, F., & Haber, D. A. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00706-2 · Cited by 474
BID regulation by p53 contributes to chemosensitivity
Sax, J. K., Fei, P., Murphy, M. E., Bernhard, E., Korsmeyer, S. J., & El-Deiry, W. S. (2002) · Nature Cell Biology · doi:10.1038/ncb866 · Cited by 420
Self-citation
The role of p53 in chemosensitivity and radiosensitivity
El‐Deiry, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206949 · Cited by 337
Self-citation
Activation and activities of the p53 tumour suppressor protein
Bálint, É., & Vousden, K. H. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2128 · Cited by 315
Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: Implications for cancer therapy
Henson, E. S., & Gibson, S. B. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2006.05.015 · Cited by 302
The common and distinct target genes of the p53 family transcription factors
Harms, K. L., Nozell, S. E., & Chen, X. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3304-4 · Cited by 303
Cell surface Death Receptor signaling in normal and cancer cells
Özören, N., & El‐Deiry, W. S. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00131-1 · Cited by 292
Self-citation
To die or not to die: how does p53 decide?
Slee, E. A., O’Connor, D. J., & Lü, X. (2004) · Oncogene · doi:10.1038/sj.onc.1207516 · Cited by 282
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam, D., Szegezdi, É., Keane, M., de Jong, S., & Samali, A. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.11.006 · Cited by 271
Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells
Nakata, S., Yoshida, T., Horinaka, M., Shiraishi, T., Wakada, M., & Sakai, T. (2004) · Oncogene · doi:10.1038/sj.onc.1207830 · Cited by 268
Death Receptor Regulation and Celecoxib-Induced Apoptosis in Human Lung Cancer Cells
Liu, X., Yue, P., Zhou, Z., Khuri, F. R., & Sun, S. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh322 · Cited by 266
Following a TRAIL: Update on a ligand and its five receptors
Kimberley, F. C., & Screaton, G. R. (2004) · Cell Research · doi:10.1038/sj.cr.7290236 · Cited by 255
Apoptosis regulators and their role in tumorigenesis
Zörnig, M., Hueber, A., Baum, W., & Evan, G. I. (2001) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(01)00031-2 · Cited by 243
Targeting apoptosis for anticancer therapy
Fulda, S. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.05.002 · Cited by 242
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
Trivedi, R., & Mishra, D. P. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00069 · Cited by 229
Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity
Malhi, H., Barreyro, F. J., Isomoto, H., Bronk, S. F., & Gores, G. J. (2007) · Gut · doi:10.1136/gut.2006.118059 · Cited by 212
New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy
Long, J. S., & Ryan, K. M. (2012) · Oncogene · doi:10.1038/onc.2012.7 · Cited by 213
How melanoma cells evade trail-induced apoptosis
Hersey, P., & Zhang, X. D. (2001) · Nature reviews. Cancer · doi:10.1038/35101078 · Cited by 214
DBC2 , a candidate for a tumor suppressor gene involved in breast cancer
Hamaguchi, M., Meth, J. L., von Klitzing, C., Wei, W., Esposito, D., Rodgers, L., Walsh, T., Welcsh, P. L., King, M., & Wigler, M. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212516099 · Cited by 211
TP53: a key gene in human cancer
Guimarães, D. P., & Hainaut, P. L. (2002) · Biochimie · doi:10.1016/s0300-9084(01)01356-6 · Cited by 209
Death receptors as targets in cancer
Micheau, O., Shirley, S., & Dufour, F. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12238 · Cited by 189
Targeting death-inducing receptors in cancer therapy
Takeda, K., Stagg, J., Yagita∥, H., Okumura, K., & Smyth, M. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210374 · Cited by 187
The Bile Acid Glycochenodeoxycholate Induces TRAIL-Receptor 2/DR5 Expression and Apoptosis
Higuchi, H., Bronk, S. F., Takikawa, Y., Werneburg, N. W., Takimoto, R., El‐Deiry, W. S., & Gores, G. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105300200 · Cited by 186
Self-citation
p53 Upregulates Death Receptor 4 Expression through an Intronic p53 Binding Site
Liu, X., Yue, P., Khuri, F. R., & Sun, S.-Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1195 · Cited by 184
Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells
Horinaka, M., Yoshida, T., Shiraishi, T., Nakata, S., Wakada, M., Nakanishi, R., Nishino, H., Matsui, H., & Sakai, T. (2005) · Oncogene · doi:10.1038/sj.onc.1208874 · Cited by 180
TNF-related apoptosis-inducing ligand (TRAIL): A new path to anti-cancer therapies
Holoch, P. A., & Griffith, T. S. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.06.066 · Cited by 181
Proteasome Inhibitor MG132 Induces Death Receptor 5 through CCAAT/Enhancer-Binding Protein Homologous Protein
Yoshida, T., Shiraishi, T., Nakata, S., Horinaka, M., Wakada, M., Mizutani, Y., Miki, T., & Sakai, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0693 · Cited by 173
Expression of TRAIL and TRAIL receptors in normal and malignant tissues
DANIELS, R. A., Turley, H., Kimberley, F. C., Xue Song, L. I. U., Mongkolsapaya, J., CH'EN, P., Xu, X. N., Jin, B., Pezzella, F., & Screaton, G. R. (2005) · Cell Research · doi:10.1038/sj.cr.7290311 · Cited by 176
Chemoresistance in solid tumours
Wilson, T. R., Longley, D. B., & Johnston, P. G. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl280 · Cited by 176
Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy
van Geelen, C. M. M., de Vries, E. G. E., & de Jong, S. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.11.002 · Cited by 167
c-Jun NH2-Terminal Kinase-Mediated Up-regulation of Death Receptor 5 Contributes to Induction of Apoptosis by the Novel Synthetic Triterpenoid Methyl-2-Cyano-3,12-Dioxooleana-1, 9-Dien-28-Oate in Human Lung Cancer Cells
Zou, W., Liu, X., Yue, P., Zhou, Z., Sporn, M. B., Lotan, R., Khuri, F. R., & Sun, S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1238 · Cited by 167
Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis
Shankar, S., Ganapathy, S., Chen, Q., & Srivastava, R. K. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-16 · Cited by 157
Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes
Rubio-Moscardo, F. (2005) · Blood · doi:10.1182/blood-2005-05-2013 · Cited by 157
Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP
Galligan, L., Longley, D. B., McEwan, M. V., Wilson, T. R., McLaughlin, K. M., & Johnston, P. G. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0262 · Cited by 155
P53 protein in proliferation, repair and apoptosis of cells
Wawryk‐Gawda, E., Chylińska‐Wrzos, P., Lis-Sochocka, M., Chłapek, K., Bulak, K., Jędrych, M., & Jodłowska‐Jędrych, B. (2013) · PROTOPLASMA · doi:10.1007/s00709-013-0548-1 · Cited by 155
The transcription factor p53: Not a repressor, solely an activator.
Fischer, M., Steiner, L., & Engeland, K. (2014) · Cell Cycle · doi:10.4161/15384101.2014.949083 · Cited by 153
NF‐κB pathway: a target for preventing β‐amyloid (Aβ)‐induced neuronal damage and Aβ42 production
Valerio, A., Boroni, F., Benarese, M., Sarnico, I., Ghisi, V., Bresciani, L. G., Ferrario, M., Borsani, G., Spano, P., & Pizzi, M. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04722.x · Cited by 148
Rational bases for the development of EGFR inhibitors for cancer treatment
Bianco, R., Gelardi, T., Damiano, V., Ciardiello, F., & Tortora, G. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.05.008 · Cited by 144
Targeting apoptotic pathways for cancer therapy
Tian, X., Srinivasan, P. R., Tajiknia, V., Uruchurtu, A. F. S. S., Seyhan, A. A., Carneiro, B. A., Cruz, A. D. L., Pinho-Schwermann, M. P., George, A., Zhao, S., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci179570 · Cited by 155
Self-citation
Apoptosis in cancer—implications for therapy
Schulze‐Bergkamen, H., & Krammer, P. H. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.11.006 · Cited by 146
Bile Acids Up-regulate Death Receptor 5/TRAIL-receptor 2 Expression via a c-Jun N-terminal Kinase-dependent Pathway Involving Sp1
Higuchi, H., Grambihler, A., Canbay, A. E., Bronk, S. F., & Gores, G. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m309476200 · Cited by 140
TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy
Wajant, H., Pfizenmaier, K., & Scheurich, P. (2002) · APOPTOSIS · doi:10.1023/a:1020039225764 · Cited by 142
The pro-longevity gene FoxO3 is a direct target of the p53 tumor suppressor
Renault, V. M., Thekkat, P. U., Hoang, K., White, J. L., Brady, C. A., Brož, D. K., Venturelli, O. S., Johnson, T. M., Oskoui, P. R., Xuan, Z., et al. (2011) · Oncogene · doi:10.1038/onc.2011.35 · Cited by 139
Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.
Spierings, D. C. J., de Vries, E. G. E., Timens, W., Groen, H. J. M., Boezen, H. M., & de Jong, S. (2003) · PubMed · Cited by 138
Transcription Factor NF-κB Differentially Regulates Death Receptor 5 Expression Involving Histone Deacetylase 1
Shetty, S., Graham, B. A., Brown, J. G., Hu, X., Vegh-Yarema, N., Harding, G. A., Paul, J. T., & Gibson, S. B. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5404-5416.2005 · Cited by 136
Regulation of p53 tumour suppressor target gene expression by the p52 NF‐κB subunit
Schumm, K., Rocha, S., Caamaño, J., & Perkins, N. D. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601343 · Cited by 135
Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling
El‐Deiry, W. S. (2001) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400943 · Cited by 136
Self-citation
Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5
Carter, B. Z., Mak, D. H. F., Schober, W. D., Dietrich, M. F., Pinilla, C., Vassilev, L. T., Reed, J. C., & Andreeff, M. (2008) · Blood · doi:10.1182/blood-2007-05-091504 · Cited by 134
Evidence that the death receptor DR4 is a DNA damage‐inducible, p53‐regulated gene
Guan, B., Yue, P., Clayman, G. L., & Sun, S. (2001) · Journal of Cellular Physiology · doi:10.1002/jcp.1101 · Cited by 135
Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo
Burns, T. F., Bernhard, E. J., & El‐Deiry, W. S. (2001) · Oncogene · doi:10.1038/sj.onc.1204484 · Cited by 138
Self-citation
Baicalein Overcomes Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Resistance via Two Different Cell-Specific Pathways in Cancer Cells but not in Normal Cells
Taniguchi, H., Yoshida, T., Horinaka, M., Yasuda, T., Goda, A. E., Konishi, M., Wakada, M., Kataoka, K., Yoshikawa, T., & Sakai, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1120 · Cited by 132
The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce Apoptosis
Takimoto, R., Wang, W., Dicker, D. T., Rastinejad, F., Lyssikatos, J. P., & El‐Deiry, W. S. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.1.1.41 · Cited by 130
Self-citation
The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor–related apoptosis-inducing ligand
Horinaka, M., Yoshida, T., Shiraishi, T., Nakata, S., Wakada, M., & Sakai, T. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0431 · Cited by 127
Ursolic Acid, a Pentacyclin Triterpene, Potentiates TRAIL-induced Apoptosis through p53-independent Up-regulation of Death Receptors
Prasad, S., Yadav, V. R., Kannappan, R., & Aggarwal, B. B. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.183699 · Cited by 124
Retracted
Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance
Zingoni, A., Fionda, C., Borrelli, C., Cippitelli, M., Santoni, A., & Soriani, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01194 · Cited by 126
DDIT3 and KAT2A Proteins Regulate TNFRSF10A and TNFRSF10B Expression in Endoplasmic Reticulum Stress-mediated Apoptosis in Human Lung Cancer Cells
Li, T., Su, L., Lei, Y., Liu, X., Zhang, Y., & Liu, X. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.645333 · Cited by 123
Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL‐R2 gene 1
Yoshida, T., Maeda, A., Tani, N., & Sakai, T. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02947-7 · Cited by 124
Coupling of Endoplasmic Reticulum Stress to CDDO-Me–Induced Up-regulation of Death Receptor 5 via a CHOP–Dependent Mechanism Involving JNK Activation
Zou, W., Yue, P., Khuri, F. R., & Sun, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1318 · Cited by 119
Identification of Novel p53 Target Genes in Ionizing Radiation Response
Jen, K., & Cheung, V. G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1039 · Cited by 119
Rel/NF-κB Transcription Factors Protect against Tumor Necrosis Factor (TNF)-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by Up-regulating the TRAIL Decoy Receptor DcR1
Bernard, D., Quatannens, B., Vandenbunder, B., & Abbadie, C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011183200 · Cited by 121
Death to the bad guys: Targeting cancer via Apo2L/TRAIL
Bouralexis, S., Findlay, D. M., & Evdokiou, A. (2005) · APOPTOSIS · doi:10.1007/s10495-005-6060-0 · Cited by 119
Targeted Therapies to Improve Tumor Immunotherapy
Begley, J. L., & Ribas, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4804 · Cited by 118
Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation
Zhou, J., Lu, G., Ong, C.-S., Ong, C. N., & Shen, H. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0071 · Cited by 116
The biological role of the Fas/FasL system during tumor formation and progression
Ernst Reichmann, A. (2002) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00017-2 · Cited by 116
Death squads enlisted by the tumour suppressor p53
Michalak, E. M., Villunger, A., Erlacher, M., & Strasser, A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.183 · Cited by 116
Apoptotic Pathways and Therapy Resistance in Human Malignancies
Viktorsson, K., Lewensohn, R., & Zhivotovsky, B. (2005) · Advances in cancer research · doi:10.1016/s0065-230x(05)94004-9 · Cited by 111
Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors.
Terui, T., Murakami, K., Takimoto, R., Takahashi, M., Takada, K., Murakami, T., Minami, S., Matsunaga, T., Takayama, T., Kato, J., et al. (2003) · PubMed · Cited by 104
Self-citation
Inducible Silencing of KILLER/DR5 In vivo Promotes Bioluminescent Colon Tumor Xenograft Growth and Confers Resistance to Chemotherapeutic Agent 5-Fluorouracil
Wang, S., & El‐Deiry, W. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1734 · Cited by 104
Self-citation
On the TRAIL to apoptosis
Baetu, T. M., & Hiscott, J. B. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(02)00006-0 · Cited by 103
Oligodendrocyte injury in multiple sclerosis: a role for p53
Wosik, K., Antel, J. P., Kuhlmann, T., Brück, W., Bernard Massie, B., & Nalbantoglu, J. N. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01674.x · Cited by 102
RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53
Sohr, S., & Engeland, K. (2008) · Cell Cycle · doi:10.4161/cc.7.21.7014 · Cited by 103
Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression
Ivanov, V. N., Partridge, M. A., Johnson, G. E., Huang, S. X. L., Zhou, H., & Hei, T. K. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.12.012 · Cited by 100
Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB.
Yang, X., Merchant, M. S., Romero, M. E., Tsokos, M., Wexler, L. H., Kontny, U., Mackall, C. L., & Thiele, C. J. (2003) · PubMed · Cited by 96
Regulation of Programmed Cell Death by the P53 Pathway
Kuribayashi, K., & El‐Deiry, W. S. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-1-4020-6554-5_10 · Cited by 95
Self-citation
Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway
He, Q., Lee, D. I., Rong, R., Yu, M., Luo, X., Klein, M., El‐Deiry, W. S., Huang, Y. K., Hussain, A., & Sheikh, M. S. (2002) · Oncogene · doi:10.1038/sj.onc.1205345 · Cited by 94
Self-citation
Parthenolide sensitizes hepatocellular carcinoma cells to trail by inducing the expression of death receptors through inhibition of STAT3 activation
Carlisi, D., D’Anneo, A., Angileri, L., Lauricella, M., Emanuele, S., Santulli, A., Vento, R., & Tesoriere, G. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22494 · Cited by 93
A global suppressor motif for p53 cancer mutants
Baroni, T. E., Wang, T., Hua, Q., Dearth, L. R., Truong, L. N., Zeng, J., Denes, A. E., Chen, S. W., & Brachmann, R. K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401162101 · Cited by 93
mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation
He, K., Zheng, X., Li, M., Zhang, L., & Yu, J. (2015) · Oncogene · doi:10.1038/onc.2015.79 · Cited by 93
Studies on search for bioactive natural products targeting TRAIL signaling leading to tumor cell apoptosis
Ishibashi, M., & Ohtsuki, T. (2008) · Medicinal Research Reviews · doi:10.1002/med.20123 · Cited by 92
Decoy Receptor 2 ( DcR2 ) Is a p53 Target Gene and Regulates Chemosensitivity
Liu, X., Yue, P., Khuri, F. R., & Sun, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0939 · Cited by 95
Gene-specific repression of the p53 target gene PUMA via intragenic CTCF–Cohesin bindingPreprint
Gomes, N. P., & Espinosa, J. M. (2010) · Genes & Development · doi:10.1101/gad.1881010 · Cited by 94
Spatial dynamics of TRAIL death receptors in cancer cells
Twomey, J. D., Kim, S.-R., Zhao, L., Bozza, W. P., & Zhang, B. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.001 · Cited by 97
Staf50 is a novel p53 target gene conferring reduced clonogenic growth of leukemic U-937 cells
Obad, S., Brunnström, H., Vallon-Christersson, J., Borg, Å., Drott, K., & Gullberg, U. (2004) · Oncogene · doi:10.1038/sj.onc.1207524 · Cited by 90
The p53 network: p53 and its downstream genes
Shu, K., Li, B., & Wu, L. (2006) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2006.11.003 · Cited by 91
Notch1 Signaling Sensitizes Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in Human Hepatocellular Carcinoma Cells by Inhibiting Akt/Hdm2-mediated p53 Degradation and Up-regulating p53-dependent DR5 Expression
Wang, C., Qi, R., Li, N., Wang, Z., An, H., Zhang, Q., Yu, Y., & Cao, X. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.002105 · Cited by 90
Retracted
Cholestasis Increases Tumor Necrosis Factor-Related Apoptotis-Inducing Ligand (TRAIL)-R2/DR5 Expression and Sensitizes the Liver to TRAIL-Mediated Cytotoxicity
Higuchi, H., Bronk, S. F., Taniai, M., Canbay, A. E., & Gores, G. J. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.040030 · Cited by 88
Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor α expression via activation of nuclear factor-κB
Sato, Y., Kato, J., Takimoto, R., Takada, K., Kawano, Y., Miyanishi, K., Kobune, M., Sato, Y., Takayama, T., Matunaga, T., et al. (2006) · Gut · doi:10.1136/gut.2005.070417 · Cited by 88
Self-citation
Wogonin and Related Natural Flavones Overcome Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Protein Resistance of Tumors by Down-regulation of c-FLIP Protein and Up-regulation of TRAIL Receptor 2 Expression
Ding, J., Polier, G., Köhler, R., Giaisi, M., Krammer, P. H., & Li‐Weber, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.286526 · Cited by 88
Transcriptomic profiling reveals p53 as a key regulator of doxorubicin-induced cardiotoxicity
McSweeney, K. M., Bozza, W. P., Alterovitz, W.-L., & Zhang, B. (2019) · Cell Death Discovery · doi:10.1038/s41420-019-0182-6 · Cited by 86
Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression
Du, J., Liang, X., Liu, Y., Qu, Z., Gao, L., Han, L., Liu, S., Cui, M., Shi, Y., Zhang, Z., et al. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.144 · Cited by 87
Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1
Huerta‐Yépez, S., Vega, M. I., Escoto-Chavez, S. E., Murdock, B. J., Sakai, T., Baritaki, S., & Bonavida, B. (2008) · Nitric Oxide · doi:10.1016/j.niox.2008.08.001 · Cited by 86
TRAIL combinations: The new ‘trail’ for cancer therapy (Review)
Refaat, A., Abdrabou, A., & Reda, A. M. (2014) · Oncology Letters · doi:10.3892/ol.2014.1922 · Cited by 87
BRCA1 Transcriptionally Regulates Damaged DNA Binding Protein (DDB2) In the DNA Repair Response Following UV-Irradiation
Takimoto, R., MacLachlan, T. K., Dicker, D. T., Niitsu, Y., Mori, T., & El‐Deiry, W. S. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.65 · Cited by 92
Self-citation

Authors: Takimoto, R., & El-Deiry, W. S.
Affiliations: Howard Hughes Medical Institute (US)
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2000-03-30
Volume: 19
Issue: 14
Pages: 1735-1743
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/sj.onc.1203489
OpenAlex: W2053301688
Cited by: 360
References: 39
Citations by year: 2026: 3 · 2025: 6 · 2024: 3 · 2023: 12 · 2022: 5 · 2021: 6 · 2020: 11 · 2019: 10 · 2018: 7 · 2017: 10 · 2016: 8 · 2015: 10 · 2014: 12 · 2013: 8 · 2012: 18
FWCI: 7.78
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Funders: Howard Hughes Medical Institute
Japan Health Sciences Foundation
National Cancer Institute (P01CA075138, P01 CA75138-01)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords: p53, DR5, TRAIL, p53 target genes, intronic enhancer, transcriptional activation, doxorubicin, p53 stabilization, apoptosis, E6 oncoprotein
MeSH terms: Binding Sites, DNA, DNA Damage, Doxorubicin, Humans, Introns, Oncogene Proteins, Viral, Promoter Regions, Genetic, Tumor Cells, Cultured, Transcriptional Activation, Gene Expression, Tumor Suppressor Protein p53, Mutagenesis, Apoptosis, Genes, Reporter, Receptors, Tumor Necrosis Factor, Receptors, TNF-Related Apoptosis-Inducing Ligand

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks